Use of cyclooxygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nested case‐control study using a nationwide population‐based data

The study aimed to investigate the relationship between the use of COX inhibitors and the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) using a nationwide population‐based data. A nested case‐control study was conducted using the National Health Insura...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2020-01, Vol.27 (1), p.68-73
Main Authors: Cho, Kyoung Sun, Sohn, Won, Lee, Yeong Chan, Chi, Sang Ah, Cho, Ju‐Yeon, Kim, Kyunga, Paik, Yong‐Han
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antiviral agents
Antiviral Agents - therapeutic use
Carcinoma, Hepatocellular - virology
Case-Control Studies
chemoprevention
chronic hepatitis B
Cohort Studies
Cyclooxygenase Inhibitors - therapeutic use
cyclooygenase inhibitor
Female
Hepatitis
Hepatitis B
Hepatitis B, Chronic - drug therapy
Hepatocellular carcinoma
Humans
Interferon
Liver cancer
Liver diseases
Liver Neoplasms - virology
Male
Mass Screening
Middle Aged
Odds Ratio
Population studies
Population-based studies
Prostaglandin endoperoxide synthase
Republic of Korea
Risk Factors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to investigate the relationship between the use of COX inhibitors and the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) using a nationwide population‐based data. A nested case‐control study was conducted using the National Health Insurance Service–National Sample Cohort (NHIS‐NSC) from 2002 to 2013 in Korea. We compared the use of COX inhibitors between HCC cases and matched controls by categorizing 5 groups according to the cumulative defined daily dose (cDDD, 360) adjusting the use of antiviral agents. A total of 4980 patients with CHB were analysed as 996 HCC cases and 3984 matched controls. The number of COX inhibitor users (≥28 cDDD) was 358 patients (36%) and 1814 patients (45%) in the HCC group and control group, respectively. The use of COX inhibitors was significantly associated with a decreased risk of HCC development compared with nonusers (adjusted odds ratio [OR] 0.62, 95% confidence interval [CI] 0.52‐0.73, P 360 cDDDs, respectively (P 
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13201